EarliTec Diagnostics, Inc.

You’re invited! EarliPoint customer Hope Haven is hosting a free virtual and in-person continuing education program on using EarliPoint™ to diagnose and assess autism in children 16-30 months of age. 📅 Date & Time: Thursday, June 13th 12:00-1:00 PM ET 📍 Location: Virtual or in-person in Jacksonville, FL Allison Cato Jackson and the Hope Haven team will discuss their clinical experience using EarliPoint™ Evaluation, share a few de-identified case examples, and explore future implications for the rapid identification of toddlers with potential social or cognitive development delays. Reserve your spot now: https://lnkd.in/gMDJ2yPN #HopeHaven #EarliTec #EarliPoint #Diagnostics #Innovation #Webinar #AutismAwareness 

It was an energizing day today attending the Digital Biomarker Summit in NY, hosted by Regeneron. Sreenivasan (Sreeni) Narayanan and Dr. Warren Jones attended and connected with other industry thought leaders about the latest developments shaping the future of digital measurement and digital endpoints. We had the opportunity to present EarliTec Diagnostics’ poster, showcasing how social visual engagement-based biomarkers can be used to provide quantitative and objective outcome measures for autism. For a high-resolution version of the poster, check the comments below. #EarliTecDiagnostics #HealthcareInnovation #DigitalBiomarker

Thank you to MD+DI, for highlighting our groundbreaking EarliPoint Evaluation, which is revolutionizing autism diagnosis and assessment. In the piece, our CTO, Sreenivasan (Sreeni) Narayanan, discusses how our innovative technology streamlines the autism diagnosis process for clinicians and families, and successfully navigates the typical challenges associated with AI solutions. #EarlitecInnovation #HealthcareTechnology #HealthcareInnovation

🎉 We're thrilled to announce that EarliPoint brought home the Silver from the prestigious Edison Awards last week! A heartfelt thank you to our dedicated team and to all our supporters. EarliTec shares this achievement with the autism community, and we pledge to continue our mission to make earlier identification and treatment of autism accessible to children everywhere. #EdisonAwards #Innovation #HealthcareExcellence 

In a recent TechCrunch interview, our CEO Thomas Ressemann discussed the challenges with traditional autism diagnoses, often involving lengthy assessments with significant waitlists. EarliTec addresses this by offering an objective and streamlined diagnostic process, enabling clinicians to improve care. Learn more about EarliPoint and our mission to improve access in autism care from TechCrunch 👇 #AutismAcceptanceMonth #HealthTech #Innovation https://rb.gy/3c1dn3 LBL2-1033 Rev. A

At EarliTec, we believe in understanding, supporting, and celebrating every individual's unique journey. April marks #AutismAcceptanceMonth, a time to not only increase awareness but also promote acceptance and ignite change for our community. We are proud to support the community through our ongoing initiatives and collaborations. We’re committed to making earlier identification and treatment of autism accessible to children everywhere. #Autism  #AutismAwareness  #NeuroDiversity

#ICYMI: We secured $21.5M in our Series B! Funds from this round will enable us to accelerate the commercialization of our first-in-class EarliPoint Evaluation and get it to toddlers and families who deserve better care. Hear from our CEO, Thomas Ressemann.👇 #InnovativeHealthcare #EarlyDiagnosis #EarliTecSuccess #HealthTech #Autism #SeriesB

#NEWS: We secured $21.5 million in our Series B financing, with our valued investors Nexus NeuroTech Ventures and Venture Investors Health Fund leading the round. We are thrilled for this new stage of growth, which gets us closer to realizing our vision of revolutionizing autism care. Want to learn more? Check out our press release in the comments.👇 #AutismAwareness #MedicalInnovation #EarliTec #SeriesBFunding #EarliPoint

HEALTH, MEDICAL & BIOTECH: DIAGNOSTIC TECHNOLOGIES — Alinity i TBI lab test by Abbott: Abbott’s Alinity i TBI lab test is the first commercially available laboratory blood test for concussions. This test objectively measures two biomarkers in the blood that, in elevated numbers, tightly correlate to brain injury. It also rules out the need for a CT scan and will increase access to reliable TBI testing. — EarliPoint™️ Evaluation by EarliTec Diagnostics, Inc.: EarliPoint Evaluation is a first-of-its-kind advancement – an FDA-authorized tool to aid clinicians in diagnosing and assessing autism for children ages 16 to 30 months of age. EarliPoint Evaluation enables earlier identification and diagnosis of autism and removes many of the barriers that delay diagnosis today. — Galen™ Breast HER2 by Ibex Medical Analytics: Many breast cancer patients have low levels of HER2 expression and can benefit from newly developed therapies, however accurately identifying these patients is a challenge. Galen™ Breast HER2 augments the pathologist’s diagnosis and supports treatment decisions with AI-powered insights providing precise, rapid, reproducible biomarker scoring — #EdisonAwards2024 #2024EdisonAwardsFinalist #health #medical #biotech 

What makes EarliPoint™ different from other #AutismDiagnosis tools? “It allows a non-biased objective evaluation, because it doesn't discriminate. It doesn't see race. It doesn't see culture" said Erin Brooker Lozott, program director at Els for Autism. Learn more here: https://lnkd.in/ghNPqCFu #autism #MedTech #MedDevice